Bridgefront Capital’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$307K Buy
+3,921
New +$267K 0.08% 375
2025
Q4
– Sell
-6,815
Closed -$500K – 631
2025
Q3
$500K Buy
6,815
+295
+5% +$19.6K 0.15% 249
2025
Q2
$339K Buy
+6,520
New +$371K 0.09% 393
2023
Q4
– Sell
-6,238
Closed -$238K – 446
2023
Q3
$238K Buy
+6,238
New +$256K 0.17% 274
2021
Q3
– Sell
-9,230
Closed -$419K – 481
2021
Q2
$419K Buy
9,230
+4,142
+81% +$183K 0.16% 230
2021
Q1
$212K Sell
5,088
-6,916
-58% -$316K 0.07% 561
2020
Q4
$513K Buy
+12,004
New +$431K 0.18% 201

Other funds holding HALO

Bridgefront Capital's HALO Position: Q2 2026 in Review

Bridgefront Capital opened a new position in Halozyme (HALO) in Q2 2026: 3,921 shares worth $307K. The stake represents 0.08% of the portfolio and ranks #375 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in HALO as recently as Q3 2025.

Bridgefront Capital first reported a position in HALO in Q4 2020 and has held it in 7 quarters since. The position peaked at $513K in Q4 2020. 674 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Bridgefront Capital held 3,921 shares of Halozyme worth $307K as of Q2 2026.
  • Halozyme was a new Bridgefront Capital position in Q2 2026.
  • Halozyme made up 0.08% of Bridgefront Capital's portfolio in Q2 2026, its #375 holding.
  • Bridgefront Capital first reported a position in Halozyme in Q4 2020 and has held it in 7 quarters since.
  • Bridgefront Capital's Halozyme position peaked at $513K in Q4 2020.
  • 674 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.